Pharma Warns On O'Neill Levy Idea But Wants To Join Global AMR Fight
Executive Summary
The drugs industry has slammed the O'Neill AMR Review's proposal that pharma pays for a big part of the bill for tackling antimicrobial resistance – warning it could delay a solution and illustrating how difficult it might be to forge the collective worldwide response that the report calls for.
You may also be interested in...
Pharma's Latest Davos Pledge: Sincere, Or Just Keeping Up Appearances?
Many hope the "dialogue of the deaf" between pharma and other healthcare stakeholders can be truly bridged by the industry's latest Davos declaration to collaborate in targeting chronic diseases of the poor.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.